Literature DB >> 12109911

Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine.

Håkan V Wikström1, Marguérite M Mensonides-Harsema, Thomas I F H Cremers, Ejner K Moltzen, Jørn Arnt.   

Abstract

The synthesis and resolution of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin (6-methoxymianserin, 6) are described. Furthermore, the in vitro and in vivo effects of 6 and its enantiomers are presented. 6 displayed high affinity for the 5-HT2A/2C receptors, only moderate affinity for the adrenoceptors, and no affinity for the NA reuptake site. Surprisingly, 6 also showed moderate to high affinity for the dopamine D2 receptor, an effect that resides in the (R)-(-)-enantiomer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109911     DOI: 10.1021/jm010566d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  α2-Adrenoceptors are targets for antipsychotic drugs.

Authors:  Jan Brosda; Florian Jantschak; Heinz H Pertz
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

2.  Mirtazapine and ketanserin alter preference for gambling-like schedules of reinforcement in rats.

Authors:  Amanda L Persons; Stephanie E Tedford; T Celeste
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-04-12       Impact factor: 5.067

3.  Neuroimaging of mirtazapine enantiomers in humans.

Authors:  Donald F Smith; Søren B Hansen; Steen Jakobsen; Dirk Bender; Hélène Audrain; Mahmoud Ashkanian; Bo S Stork; Luciano Minuzzi; Håkan Hall; Raben Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

4.  [N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans.

Authors:  Katalin Marthi; Steen Jakobsen; Dirk Bender; Søren B Hansen; Stefan Bo Smith; Flemming Hermansen; Raben Rosenberg; Donald F Smith
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

5.  3D-QSAR design of new escitalopram derivatives for the treatment of major depressive disorders.

Authors:  Speranta Avram; Catalin Buiu; Daniel M Duda-Seiman; Corina Duda-Seiman; Dan Mihailescu
Journal:  Sci Pharm       Date:  2010-05-05

Review 6.  Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects.

Authors:  Yukihiro Ohno; Naofumi Kunisawa; Saki Shimizu
Journal:  Front Pharmacol       Date:  2019-09-17       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.